CN215986103U - Mycoplasma pneumoniae and chlamydia pneumoniae antibody joint detection kit - Google Patents
Mycoplasma pneumoniae and chlamydia pneumoniae antibody joint detection kit Download PDFInfo
- Publication number
- CN215986103U CN215986103U CN202122100672.8U CN202122100672U CN215986103U CN 215986103 U CN215986103 U CN 215986103U CN 202122100672 U CN202122100672 U CN 202122100672U CN 215986103 U CN215986103 U CN 215986103U
- Authority
- CN
- China
- Prior art keywords
- reagent strip
- igg
- igm
- antibody
- pneumoniae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The utility model discloses a mycoplasma pneumoniae and chlamydia pneumoniae antibody joint inspection kit, which comprises a first reagent strip and a second reagent strip, wherein the first reagent strip is a mycoplasma pneumoniae and chlamydia pneumoniae IgM detection reagent strip, the second reagent strip is a mycoplasma pneumoniae and chlamydia pneumoniae IgG detection reagent strip, a colloidal gold-labeled IgM antibody-biotin-avidin-colloidal gold compound is coated on a binding pad of the first reagent strip, and a colloidal gold-labeled IgG antibody-biotin-avidin-colloidal gold compound is coated on a binding pad of the second reagent strip. The joint inspection kit avoids mutual interference between IgG antibodies and IgM antibodies, improves the accuracy of joint inspection, can simultaneously detect the IgM antibodies and IgG antibodies of mycoplasma pneumoniae and chlamydia pneumoniae, and can well meet the requirement of clinical detection.
Description
Technical Field
The utility model belongs to the field of in-vitro diagnostic reagents, and particularly relates to a combined detection kit for antibodies of mycoplasma pneumoniae and chlamydia pneumoniae.
Background
Pneumonia has been one of the common infectious diseases threatening human health and also a major cause of global economic loss. Pneumonia is divided into a large number of categories, with community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP) being the leading causes of morbidity and mortality in pneumonia worldwide. Community-acquired pneumonia (CAP) refers to an infectious inflammation of the lung parenchyma that occurs outside a hospital, including pneumonia that occurs in a latent period after admission due to infection with a pathogen with a defined latent period. Mild symptomatic CAP may be caused by mycoplasma pneumoniae, chlamydia pneumoniae and viruses, and the joint detection of mycoplasma pneumoniae and chlamydia pneumoniae is essential for early diagnosis and treatment of community-acquired pneumonia.
Mycoplasma Pneumoniae (MP) belongs to the class mollicutes and the genus Mycoplasma, is the smallest non-staining cell wall-free prokaryotic microorganism which is between viruses and bacteria and is difficult to stain, and has slow growth, long culture period and difficult in-vitro separation culture. MP is one of the common pathogens causing respiratory infections and community-acquired pneumonia in children and adults. MP is infected by droplets, has long incubation period and disease course, and is common and easy to feel by people. Due to low resistance of children, age 2-4 years is an infection-susceptible age. After MP infection, mild respiratory tract infection, pharyngitis, tonsillitis, bronchitis, SARS, etc. may be caused, and encephalitis, myocarditis, hepatitis, etc. may be caused.
Chlamydia Pneumoniae (CP), another major pathogen of CAP, is responsible for respiratory and pulmonary infections. CP infection is a common disease widely existing all over the world, has no obvious sex and regional difference, can occur all the year round, almost every person is infected in one life, and people of different ages are susceptible to repeated infection. Chlamydia pneumoniae is transmitted by droplets, and asymptomatic infectors are more important than patients in the spread of the disease. The chlamydia pneumoniae mainly causes atypical pneumonia of human, and can cause diseases such as bronchitis, pharyngitis, sinusitis, otitis media, iritis, hepatitis, myocarditis, endocarditis, meningitis, erythema nodosum and the like, and is also one of important pathogenic bacteria of secondary infection such as AIDS, leukemia and the like
Immunoglobulin M (IgM) and Immunoglobulin G (IgG) are the two most important antibodies in humans. Generally, IgM appears at an early stage of viral infection, approximately 1 week after viral infection, and is a diagnostic indicator of acute stage infection, but at relatively low concentrations, short maintenance times, and low affinity. IgG appears about 3 weeks after infection with the virus and is present in the blood circulation for a long time, depending on factors such as the particular pathogenic mechanism, latency, etc. of the virus-infected organism. By detecting the existence of specific IgM and IgG antibodies in vivo, the immune reaction state of a human body to virus infection can be diagnosed. If a specific IgM antibody is detected, the occurrence of recent infection is shown, but the half-life of the IgM antibody is short, the detection of IgM is negative, the body is not infected, and IgG antibodies with long half-life and high content need to be detected to make a definite diagnosis. The detection result is only used for clinical reference, and clinical diagnosis of the patient should be comprehensively considered in combination with other information such as laboratory examination.
CN201210461987.8 discloses a colloidal gold method detection test paper strip and a kit for IgM and IgG antibodies of mycoplasma pneumoniae and a preparation method thereof. The test strip gold label pad is coated with a recombinant MP antigen-colloidal gold compound, and the nitrocellulose membrane is respectively coated with a detection line of a mouse anti-human IgM antibody, a detection line of a mouse anti-human IgG antibody and a quality control line of a rabbit anti-MP polyclonal antibody. In the actual detection process of the test strip, if the content of the IgG of the mycoplasma pneumoniae to be detected is too low, an incorrect negative result can be obtained.
CN201520364385.X discloses a mycoplasma pneumoniae IgM, IgG and IgA triple-joint detection card. The detection card marker pad adsorbs colloidal gold particles for marking mycoplasma pneumoniae P1 protein, the reaction membrane is provided with three detection lines and a control line, the three detection lines are respectively coated with mouse anti-human IgM, mouse anti-human IgG and mouse anti-human IgA, and the control line is goat anti-mouse IgG. In the actual detection process, if the content of the mycoplasma pneumoniae IgG to be detected is too high, cross infection with the IgM is easily caused, and the detection of the IgM is interfered.
Therefore, based on these problems, there is still a need to develop a high-accuracy combined detection kit for mycoplasma pneumoniae and chlamydia pneumoniae antibodies to meet the needs of clinical detection applications.
SUMMERY OF THE UTILITY MODEL
The utility model aims to overcome the defects of the prior art and provide the mycoplasma pneumoniae and chlamydia pneumoniae antibody joint detection kit with high accuracy.
In order to realize the purpose, the utility model provides a mycoplasma pneumoniae and chlamydia pneumoniae antibody joint inspection kit, which adopts the following technical scheme:
a combined detection kit for antibodies of mycoplasma pneumoniae and chlamydia pneumoniae is characterized by comprising a shell and a test strip arranged in the shell, the upper surface of the shell is provided with a first observation window and a second observation window which are arranged side by side, and has a rectangular structure with the same size, a first sample adding hole and a second sample adding hole are respectively arranged below the first observation window and the second observation window, the test strip comprises a first reagent strip and a second reagent strip, the first reagent strip and the second reagent strip both comprise a bottom plate, a sample pad, a combination pad, an NC film, a water absorption pad and an adhesive tape for connecting the sample pad, the combination pad and the NC film, the sample pad, the combination pad, the NC film and the water absorption pad are sequentially overlapped on the bottom plate, the first reagent strip is a reagent strip for detecting IgM of mycoplasma pneumoniae and chlamydia pneumoniae, and the second reagent strip is a reagent strip for detecting IgG of mycoplasma pneumoniae and chlamydia pneumoniae.
Furthermore, the sample pad of the first reagent strip is opposite to the first sample adding hole, the sample pad of the second reagent strip is opposite to the second sample adding hole, the NC film of the first reagent strip is opposite to the first observation window, and the NC film of the second reagent strip is opposite to the second observation window.
Further, the binding pad of the first reagent strip is coated with an IgM colloidal gold complex, and the binding pad of the second reagent strip is coated with an IgG colloidal gold complex.
Further, the IgM colloidal gold complex comprises a colloidal gold-labeled IgM antibody-biotin-avidin-colloidal gold complex, the colloidal gold-labeled IgM antibody comprises a colloidal gold-labeled murine anti-mycoplasma hyopneumoniae IgM monoclonal antibody and a colloidal gold-labeled murine anti-chlamydia pneumoniae IgM monoclonal antibody, the IgG colloidal gold complex comprises a colloidal gold-labeled IgG antibody-biotin-avidin-colloidal gold complex, and the colloidal gold-labeled IgG antibody comprises a colloidal gold-labeled murine anti-mycoplasma hyopneumoniae IgG monoclonal antibody and a colloidal gold-labeled murine anti-chlamydia hyopneumoniae IgG monoclonal antibody.
Furthermore, a CP-IgM detection line, an MP-IgM detection line and an IgM quality control line are sequentially arranged on the NC membrane of the first reagent strip from bottom to top, and a CP-IgG detection line, an MP-IgG detection line and an IgG quality control line are sequentially arranged on the NC membrane of the second reagent strip from bottom to top.
Furthermore, the CP-IgM detection line and the CP-IgG detection line are coated with Chlamydia pneumoniae proteins, the MP-IgM detection line and the MP-IgG detection line are coated with Mycoplasma pneumoniae proteins, the IgM quality control line is coated with anti-goat IgY, and the IgG quality control line is coated with anti-goat IgY.
Further, the sample pad of the first reagent strip is also coated with an IgG antibody adsorbent.
Furthermore, one end of the sample pad presses one end of the combination pad for 1-2mm, one end of the combination pad presses one end of the NC membrane for 1-2mm, one end of the water absorption pad presses one end of the NC membrane for 1-2mm, and one end of the adhesive tape presses one end of the sample pad for 0.5-1 mm.
Further, the kit also comprises a pipette and a sample diluent.
Furthermore, the straw is a single disposable quantitative straw.
Compared with the prior art, the utility model has the following beneficial effects that:
(1) the combined detection kit for the mycoplasma pneumoniae and the chlamydia pneumoniae antibodies comprises a first reagent strip and a second reagent strip which are arranged side by side, wherein the first reagent strip is used for detecting the IgM antibodies of the chlamydia pneumoniae and the mycoplasma pneumoniae, and the second reagent strip is used for detecting the IgG antibodies of the chlamydia pneumoniae and the mycoplasma pneumoniae, so that mutual interference between the IgG antibodies and the IgM antibodies is avoided, and the accuracy of combined detection is improved.
(2) The IgG antibody adsorbent is coated in the sample pad of the first reagent strip of the kit, so that the IgG antibody with high concentration in the sample can be adsorbed, the influence of the IgG antibody with high concentration on the false negative and false positive of IgM detection is further reduced, and the accuracy of joint inspection is improved.
(3) The IgM/IgG antibody-biotin-avidin-colloidal gold compound marked by colloidal gold is coated on the binding pad of the kit, so that the IgM/IgG antibody-biotin-avidin-colloidal gold compound can be detected when the content of the IgM antibody or IgG antibody in an early infection sample is low, and the accuracy of joint detection is further improved.
(4) The kit is suitable for samples such as serum, plasma or whole blood samples, can simultaneously detect IgM antibodies and IgG antibodies of mycoplasma pneumoniae and chlamydia pneumoniae, and can well meet the requirement of clinical detection.
Drawings
In order to more clearly illustrate the embodiments of the present application or technical solutions in the prior art, the drawings needed to be used in the embodiments will be briefly described below, and it is obvious that the drawings in the following description are only some embodiments described in the present invention, and other drawings can be obtained by those skilled in the art according to the drawings.
FIG. 1 is a schematic structural diagram of the Mycoplasma pneumoniae and Chlamydia pneumoniae antibody joint inspection kit of the utility model;
FIG. 2 is a schematic structural diagram of a first reagent strip of the combined detection kit for Mycoplasma pneumoniae and Chlamydia pneumoniae antibodies of the utility model;
FIG. 3 is a schematic structural diagram of a second reagent strip of the combined detection kit for Mycoplasma pneumoniae and Chlamydia pneumoniae antibodies of the utility model.
The kit comprises a 100-mycoplasma pneumoniae and chlamydia pneumoniae antibody joint inspection kit, a 110-shell, a 111-first observation window, a 112-second observation window, a 113-first sample adding hole, a 114-second sample adding hole, a 120-first reagent strip, a 121-sample pad 1, a 122-binding pad 1, a 123-NC membrane 1, a 124-water absorption pad, a 125-adhesive tape, a 126-CP-IgM detection line, a 127-MP-IgM detection line, a 128-IgM quality control line, a 129-bottom plate, a 130-second reagent strip, a 131-sample pad 2, a 132-binding pad 2, a 133-NC membrane 2, a 134-CP-IgG detection line, a 135-MP-IgG detection line and a 136-IgG quality control line.
Detailed Description
In order to make the technical solutions of the present invention better understood, those skilled in the art will now describe the present invention in further detail with reference to the accompanying drawings. It is to be understood that the described embodiments are merely exemplary of the utility model, and not restrictive of the full scope of the utility model. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention. The experimental procedures in the following examples are conventional unless otherwise specified. The test materials used in the following examples were purchased from a conventional biochemical reagent store unless otherwise specified.
As shown in fig. 1, fig. 2 and fig. 3, a mycoplasma pneumoniae and chlamydia pneumoniae antibody joint inspection kit 100 includes a casing 110 and a test strip installed in the casing, the upper surface of the casing 110 is provided with a first observation window 111 and a second observation window 112, the first observation window 111 and the second observation window 112 are arranged side by side and have rectangular structures with the same size, the lower parts of the first observation window 111 and the second observation window 112 are further respectively provided with a first sample adding hole 113 and a second sample adding hole 114, the test strip includes a first reagent strip 120 and a second reagent strip 130, the first reagent strip 120 and the second reagent strip 130 both include a bottom plate 129 and sample pads (121 or 131), binding pads (122 or 132), NC films (123 or 133), water absorption pads 124 and adhesive tapes 125 for connecting the sample pads, the binding pads and the NC films, the first reagent strip 120 is a mycoplasma pneumoniae and chlamydia pneumoniae IgM detection reagent strip, the second reagent strip 130 is a Mycoplasma pneumoniae and Chlamydia pneumoniae IgG detection reagent strip.
Specifically, the sample pad 121 of the first reagent strip is positioned opposite to the first well 113, the sample pad 131 of the second reagent strip is positioned opposite to the second well 114, the NC film 123 of the first reagent strip is positioned opposite to the first viewing window 111, and the NC film 133 of the second reagent strip is positioned opposite to the second viewing window 112. According to the kit 100 for the combined detection of the mycoplasma pneumoniae and the chlamydia pneumoniae antibodies, the first reagent strip 120 and the second reagent strip 130 are arranged side by side, the first reagent strip 120 is used for detecting the IgM antibodies of the chlamydia pneumoniae and the mycoplasma pneumoniae, and the second reagent strip 130 is used for detecting the IgG antibodies of the chlamydia pneumoniae and the mycoplasma pneumoniae, so that mutual interference between the IgG antibodies and the IgM antibodies is avoided, and the accuracy of the combined detection is improved.
Specifically, in one embodiment, the binding pad 122 of the first reagent strip is coated with IgM colloidal gold complexes and the binding pad 132 of the second reagent strip is coated with IgG colloidal gold complexes. Furthermore, the IgM colloidal gold complex comprises a colloidal gold-labeled IgM antibody-biotin-avidin-colloidal gold complex, the colloidal gold-labeled IgM antibody comprises a colloidal gold-labeled mouse anti-human mycoplasma pneumoniae IgM monoclonal antibody and a colloidal gold-labeled mouse anti-human chlamydia pneumoniae IgM monoclonal antibody, the IgG colloidal gold complex comprises a colloidal gold-labeled IgG antibody-biotin-avidin-colloidal gold complex, and the colloidal gold-labeled IgG antibody comprises a colloidal gold-labeled mouse anti-human mycoplasma pneumoniae IgG monoclonal antibody and a colloidal gold-labeled mouse anti-human chlamydia pneumoniae IgG monoclonal antibody. According to the kit, the IgM/IgG antibody marked by the colloidal gold is combined with the biotin-avidin amplification system on the combination pad, so that the IgM antibody or IgG antibody in the sample at the early stage of infection can be detected when the content of the IgM antibody or IgG antibody is low, and the accuracy of joint detection is further improved.
As shown in fig. 1, 2 and 3, the NC membrane 123 of the first reagent strip 120 is provided with a CP-IgM detection line 126, an MP-IgM detection line 127 and an IgM quality control line 128 in sequence from bottom to top, and the NC membrane 133 of the second reagent strip 130 is provided with a CP-IgG detection line 134, an MP-IgG detection line 135 and an IgG quality control line 136 in sequence from bottom to top. Furthermore, Chlamydia pneumoniae proteins are coated on the CP-IgM detection line 126 and the CP-IgG detection line 134, mycoplasma pneumoniae proteins are coated on the MP-IgM detection line 127 and the MP-IgG detection line 135, goat anti-chicken IgY is coated on the IgM quality control line 128, and goat anti-chicken IgY is coated on the IgG quality control line 136.
In one embodiment, the sample pad 121 of the first reagent strip 120 is further coated with an IgG antibody adsorbent. The IgG antibody adsorbent can adsorb high-concentration IgG antibodies in a sample, further reduce the influence of the high-concentration IgG antibodies on false negative and false positive of IgM detection, and improve the accuracy of joint inspection.
As shown in FIG. 2 and FIG. 3, in one embodiment, one end of the sample pad (121 or 131) is pressed against one end of the bonding pad (122 or 132) by 1-2mm, one end of the bonding pad (122 or 132) is pressed against one end of the NC membrane (123 or 133) by 1-2mm, one end of the absorbent pad 124 is pressed against one end of the NC membrane (123 or 133) by 1-2mm, and one end of the adhesive tape 125 is pressed against one end of the sample pad (121 or 131) by 0.5-1 mm.
In one embodiment, the kit 100 further comprises a pipette and a sample diluent. Furthermore, the straw is a single disposable quantitative straw. The pipette is used for adding a sample diluent, which is a buffer solution containing sodium chloride, and is used for diluting a sample after the sample is added. The sample suitable for the kit can be a serum sample, a plasma sample or a whole blood sample, can simultaneously detect IgM antibodies and IgG antibodies of mycoplasma pneumoniae and chlamydia pneumoniae, and can well meet the requirement of clinical detection.
The utility model discloses a detection method of mycoplasma pneumoniae and chlamydia pneumoniae antibody joint inspection kit 100:
(1) and (4) preparing. Taking out the sample to be detected and the sample diluent under the storage condition, and balancing to room temperature; and taking the reagent card out of the packaging bag, and flatly placing the reagent card on a drying plane.
(2) And (4) sample adding. a) Serum or plasma: respectively adding 10 mu L of serum or plasma samples into the first sample adding hole and the second sample adding hole, and vertically dropwise adding 2 drops of sample diluent; b) serum or plasma: 20 microliter of whole blood sample is respectively added into the first sample adding hole and the second sample adding hole, and 2 drops of sample diluent are vertically dropped.
(3) And (6) detecting. Wait for 5-10 minutes. And reading results from the first observation window and the second observation window.
The detection principle of the kit is a capture method: the test paper has colloidal gold labeled mouse anti-human IgM monoclonal antibody and mouse anti-human IgG monoclonal antibody on the combining pad, mycoplasma pneumoniae protein and chlamydia pneumoniae protein coated on the detection line (T) on the nitrocellulose membrane, and goat anti-chicken IgY antibody coated on the quality control line (C). During detection, when IgM or IgG is contained in a sample to be detected, the IgM or IgG is combined with the mouse anti-human IgM monoclonal antibody and the mouse anti-human IgG monoclonal antibody marked by colloidal gold to form an immune complex, and the immune complex is captured and enriched at a detection line (T) by the reagents fixed on the membrane to form an M line or a G line. The colloidal gold labeled antibody diffuses to the quality control line (C) area and is captured by the antibody to form a purple-red zone of the quality control area.
The following conditions exist when the results are read from the first observation window and the second observation window: a) if the sample contains the chlamydia pneumoniae IgM antibody, the chlamydia pneumoniae IgM antibody passes through the combination pad of the first reagent strip, and is combined with the colloidal gold-labeled mouse anti-human-pneumonia chlamydia IgM monoclonal antibody-biotin-avidin-colloidal gold complex, and then the chlamydia pneumoniae IgM protein is captured at the CP-IgM detection line to form a wine red detection line. b) If the sample contains the mycoplasma pneumoniae IgM antibody, the Mycoplasma pneumoniae IgM antibody passes through the combination pad of the first reagent strip and is combined with the colloidal gold-labeled mouse anti-human mycoplasma pneumoniae IgM monoclonal antibody-biotin-avidin-colloidal gold compound, and then the Mycoplasma pneumoniae IgM antibody is captured by the Mycoplasma pneumoniae protein at the MP-IgM detection line to form a wine red detection line. c) If the sample contains the Chlamydia pneumoniae IgG antibody, the sample passes through the binding pad of the second reagent strip and is bound with the colloidal gold-labeled mouse anti-human Chlamydia pneumoniae IgG monoclonal antibody-biotin-avidin-colloidal gold compound, and then the sample is captured by the Chlamydia pneumoniae protein at the CP-IgG detection line to form a wine red detection line. d) If the sample contains mycoplasma pneumoniae IgG antibody, the mycoplasma pneumoniae IgG antibody passes through the combination pad of the second reagent strip, and is combined with the colloidal gold-labeled mouse anti-human mycoplasma pneumoniae IgG monoclonal antibody-biotin-avidin-colloidal gold compound, and further captured by chlamydia pneumoniae protein at the MP-IgG detection line to form a wine red detection line. e) No matter whether the sample contains the antibody to be detected or not, the colloidal gold compound on the bonding pad can be captured by the antibody on the quality control line to form a wine red quality control line, and if the quality control line does not appear, the kit is invalid, and the detection result is invalid.
Those of ordinary skill in the art will understand that: the discussion of any embodiment above is meant to be exemplary only, and is not intended to intimate that the scope of the disclosure, including the claims, is limited to these examples; within the idea of the utility model, also technical features in the above embodiments or in different embodiments may be combined and there are many other variations of the different aspects of the utility model as described above, which are not provided in detail for the sake of brevity. Therefore, any omissions, modifications, substitutions, improvements and the like that may be made without departing from the spirit and principles of the utility model are intended to be included within the scope of the utility model.
Claims (10)
1. A combined detection kit for antibodies of mycoplasma pneumoniae and chlamydia pneumoniae is characterized by comprising a shell and a test strip arranged in the shell, the upper surface of the shell is provided with a first observation window and a second observation window which are arranged side by side, and has a rectangular structure with the same size, a first sample adding hole and a second sample adding hole are respectively arranged below the first observation window and the second observation window, the test strip comprises a first reagent strip and a second reagent strip, the first reagent strip and the second reagent strip both comprise a bottom plate, a sample pad, a combination pad, an NC film, a water absorption pad and an adhesive tape for connecting the sample pad, the combination pad and the NC film, the sample pad, the combination pad, the NC film and the water absorption pad are sequentially overlapped on the bottom plate, the first reagent strip is a reagent strip for detecting IgM of mycoplasma pneumoniae and chlamydia pneumoniae, and the second reagent strip is a reagent strip for detecting IgG of mycoplasma pneumoniae and chlamydia pneumoniae.
2. The mycoplasma pneumoniae and chlamydia pneumoniae antibody joint inspection kit according to claim 1, wherein the sample pad of the first reagent strip is opposed to the first well, the sample pad of the second reagent strip is opposed to the second well, the NC film of the first reagent strip is opposed to the first observation window, and the NC film of the second reagent strip is opposed to the second observation window.
3. The Mycoplasma pneumoniae and Chlamydia pneumoniae antibody bioassay kit according to claim 2, wherein the bonding pad of the first reagent strip is coated with an IgM colloidal gold complex, and the bonding pad of the second reagent strip is coated with an IgG colloidal gold complex.
4. The Mycoplasma pneumoniae and Chlamydia pneumoniae antibody co-detection kit according to claim 3, wherein the IgM colloidal gold complex comprises a colloidal gold-labeled IgM antibody-biotin-avidin-colloidal gold complex, the colloidal gold-labeled IgM antibody comprises a colloidal gold-labeled murine anti-Mycoplasma pneumoniae IgM monoclonal antibody and a colloidal gold-labeled murine anti-human Chlamydia pneumoniae IgM monoclonal antibody, the IgG colloidal gold complex comprises a colloidal gold-labeled IgG antibody-biotin-avidin-colloidal gold complex, and the colloidal gold-labeled IgG antibody comprises a colloidal gold-labeled murine anti-Mycoplasma pneumoniae IgG monoclonal antibody and a colloidal gold-labeled murine anti-human Chlamydia pneumoniae IgG monoclonal antibody.
5. The Mycoplasma pneumoniae and Chlamydia pneumoniae antibody joint inspection kit according to claim 4, wherein the NC membrane of the first reagent strip is provided with a CP-IgM detection line, an MP-IgM detection line and an IgM quality control line in sequence from bottom to top, and the NC membrane of the second reagent strip is provided with a CP-IgG detection line, an MP-IgG detection line and an IgG quality control line in sequence from bottom to top.
6. The Mycoplasma pneumoniae and Chlamydia pneumoniae antibody joint inspection kit according to claim 5, wherein the CP-IgM detection line and the CP-IgG detection line are coated with Chlamydia pneumoniae proteins, the MP-IgM detection line and the MP-IgG detection line are coated with Mycoplasma pneumoniae proteins, the IgM quality control line is coated with goat anti-chicken IgY, and the IgG quality control line is coated with goat anti-chicken IgY.
7. The Mycoplasma pneumoniae and Chlamydia pneumoniae antibody joint inspection kit according to claim 6, wherein the sample pad of the first reagent strip is further coated with an IgG antibody adsorbent.
8. The Mycoplasma pneumoniae and Chlamydia pneumoniae antibody joint inspection kit according to claim 7, wherein one end of the sample pad is pressed against one end of the combination pad by 1-2mm, one end of the combination pad is pressed against one end of the NC membrane by 1-2mm, and one end of the water absorption pad is pressed against one end of the NC membrane by 1-2 mm.
9. The Mycoplasma pneumoniae and Chlamydia pneumoniae antibody bioassay kit according to claim 8, wherein the kit further comprises a pipette and a sample diluent.
10. The Mycoplasma pneumoniae and Chlamydia pneumoniae antibody bioassay kit according to claim 9, wherein the pipette is a single disposable quantitative pipette.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202122100672.8U CN215986103U (en) | 2021-09-01 | 2021-09-01 | Mycoplasma pneumoniae and chlamydia pneumoniae antibody joint detection kit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202122100672.8U CN215986103U (en) | 2021-09-01 | 2021-09-01 | Mycoplasma pneumoniae and chlamydia pneumoniae antibody joint detection kit |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN215986103U true CN215986103U (en) | 2022-03-08 |
Family
ID=80582499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202122100672.8U Active CN215986103U (en) | 2021-09-01 | 2021-09-01 | Mycoplasma pneumoniae and chlamydia pneumoniae antibody joint detection kit |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN215986103U (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113848325A (en) * | 2021-09-01 | 2021-12-28 | 深圳市爱康试剂有限公司 | Mycoplasma pneumoniae and chlamydia pneumoniae antibody joint detection kit, preparation method and detection method thereof |
-
2021
- 2021-09-01 CN CN202122100672.8U patent/CN215986103U/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113848325A (en) * | 2021-09-01 | 2021-12-28 | 深圳市爱康试剂有限公司 | Mycoplasma pneumoniae and chlamydia pneumoniae antibody joint detection kit, preparation method and detection method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Klein et al. | The role of respiratory syncytial virus and other viral pathogens in acute otitis media | |
| Rousset et al. | Comparative diagnostic potential of three serological tests for abortive Q fever in goat herds | |
| Grandien et al. | Rapid viral diagnosis of acute respiratory infections: comparison of enzyme-linked immunosorbent assay and the immunofluorescence technique for detection of viral antigens in nasopharyngeal secretions | |
| CN107765002B (en) | Colloidal gold immunochromatography test strip and preparation method and application thereof | |
| CN111273001A (en) | System for rapidly detecting new coronavirus 2019-nCoV in blood sample and preparation method thereof | |
| CN102928587A (en) | Colloidal gold method detection test strip and reagent kit for IgM and IgG antibodies of mycoplasma pneumoniae and preparation method of reagent kit | |
| WO2021159703A1 (en) | Immunochromatographic kit for rapidly detecting novel coronavirus n protein, and preparation method and application thereof | |
| CN113848325A (en) | Mycoplasma pneumoniae and chlamydia pneumoniae antibody joint detection kit, preparation method and detection method thereof | |
| He et al. | Development of a lateral flow immunoassay for the rapid diagnosis of invasive candidiasis | |
| CN104198716A (en) | Animal brucella antibody gold mark rapid detection kit | |
| CN112305218A (en) | Novel coronavirus antibody colloidal gold immune lateral chromatography detection method and application thereof | |
| CN215986103U (en) | Mycoplasma pneumoniae and chlamydia pneumoniae antibody joint detection kit | |
| CN103267844A (en) | Detection test paper strip of colloidal gold method for adenovirus IgM and IgG antibodies, kit and preparation method thereof | |
| JP4976068B2 (en) | Simple immunoassay specimen suspension and assay method | |
| CN111796096A (en) | Preparation method of novel coronavirus IgGIgM antibody combined detection reagent | |
| Campbell et al. | Quantitative serology for SARS-CoV-2 using self-collected saliva and finger-stick blood | |
| Kumar et al. | Improvement in the diagnosis of Brucella abortus infections in naturally infected water buffaloes (Bubalus bubalis) using an ELISA with a Protein-G-based indicator system | |
| US20210247395A1 (en) | Antibody pairs for use in a rapid influenza b diagnostic test | |
| CN108169475A (en) | A kind of Respiratory Syncytial Virus(RSV) IgM antibody detection kit | |
| CN106771193B (en) | A kind of immunochromatographytest test kit of herpes simplex virus type II IgM antibody | |
| Pfrepper et al. | Human parvovirus B19 serology and avidity using a combination of recombinant antigens enables a differentiated picture of the current state of infection | |
| CN108226492A (en) | A groups of porcine rotavirus Rapid ELISA detection kits | |
| US20090269733A1 (en) | Devices and Methods for the Rapid Analysis of Pathogens in Biological Fluids | |
| CN102749446A (en) | Chlamydia pneumoniae IgM (immunoglobulin M) colloidal golden method kit and preparation method thereof | |
| CN216747743U (en) | Novel coronavirus IgG, IgM and neutralizing antibody combined detection card |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GR01 | Patent grant | ||
| GR01 | Patent grant |